NCT02252887
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
Phase: Phase 2
Role: Collaborator
Start: Jan 12, 2015
Completion: Jul 24, 2025